Posted by Michael Wonder on 20 Apr 2021
Aerie Pharmaceuticals receives marketing authorisation of Roclanda 50 mcg/mL + 200 mcg/mL solution eye drops (latanoprost + netarsudil) in Great Britain
19 April 2021 - Aerie Pharmaceuticals today announced that Roclanda 50 mcg/mL + 200 mcg/mL solution eye drops (latanoprost + netarsudil) has received marketing authorisation from the Medicines and Healthcare Products Regulatory Agency in Great Britain.
Roclanda is indicated for the reduction of elevated intra-ocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction.
